OraSure Technologies, Inc. (NASDAQ:OSUR) EVP Brian Smith sold 20,000 shares of OraSure Technologies stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $17.97, for a total transaction of $359,400.00. Following the sale, the executive vice president now owns 28,075 shares in the company, valued at $504,507.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
OraSure Technologies, Inc. (OSUR) opened at $17.82 on Thursday. The stock has a market capitalization of $1,083.18, a PE ratio of 34.94, a P/E/G ratio of 4.98 and a beta of 1.43. OraSure Technologies, Inc. has a fifty-two week low of $10.75 and a fifty-two week high of $23.01.
OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. The firm had revenue of $52.00 million for the quarter, compared to analyst estimates of $50.20 million. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. OraSure Technologies’s revenue was up 46.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.13 earnings per share. research analysts predict that OraSure Technologies, Inc. will post 0.29 EPS for the current fiscal year.
A number of equities research analysts recently weighed in on the stock. BidaskClub upgraded shares of OraSure Technologies from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 20th. Canaccord Genuity restated a “buy” rating and set a $24.00 price objective on shares of OraSure Technologies in a research note on Friday, February 2nd. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a research note on Wednesday, October 25th. Finally, Jefferies Group cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $22.25.
Large investors have recently added to or reduced their stakes in the stock. Oppenheimer Asset Management Inc. acquired a new position in OraSure Technologies during the third quarter worth about $186,000. Shikiar Asset Management Inc. acquired a new position in OraSure Technologies during the fourth quarter worth about $207,000. Piedmont Investment Advisors LLC acquired a new position in OraSure Technologies during the second quarter worth about $216,000. ARP Americas LLC acquired a new position in OraSure Technologies during the third quarter worth about $221,000. Finally, Advisory Services Network LLC grew its holdings in OraSure Technologies by 1,419.2% during the second quarter. Advisory Services Network LLC now owns 12,913 shares of the medical instruments supplier’s stock worth $223,000 after acquiring an additional 12,063 shares during the period. 89.91% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/22/brian-smith-sells-20000-shares-of-orasure-technologies-inc-osur-stock.html.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.